Lupus Nephritis (LN)- Epidemiology Forecast to 2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,250	96 Pages	DelveInsight	August, 2019	DEL16007401

Best Price Guarantee
Price	from $3,250
Length	96 Pages
Publisher	DelveInsight
Published Date	August, 2019
SKU	DEL16007401

DelveInsight’s ‘Lupus Nephritis (LN)- Epidemiology Forecast to 2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Lupus Nephritis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2017-2028
Lupus Nephritis Epidemiology
The Lupus Nephritis (LN) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Lupus Nephritis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Lupus Nephritis Epidemiology Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, gender-specific prevalent cases, class-specific prevalent cases, clinical manifestations and diagnosed cases of LN) scenario of Lupus Nephritis (LN) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the total number of prevalent cases of Lupus Nephritis (LN) in 7 MM was found to be 190,819, in the year 2017.
Report Scope
• The report covers detailed overview of Lupus Nephritis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Lupus Nephritis in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by prevalence of LN, , gender based prevalence, class based prevalent cases, clinical manifestations and diagnosed cases in 7MM

Key strengths
• 10 Year Forecast of Lupus Nephritis epidemiology
• 7MM Coverage
• Total Prevalent Cases of LN
• Prevalent Cases according to segmentation: Prevalence, Types, Class Based, Clinical Manifestations and segments based gender.
• Diagnosed cases of LN
Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

1. Key Insights
2. Lupus Nephritis: Market Overview At A Glance: 2.1. Total Market Share (%) Distribution Of Lupus Nephritis In 2017; 2.2. Total Market Share (%) Distribution Of Lupus Nephritis In 2028
3. Lupus Nephritis: Disease Background And Overview: 3.1. Introduction; 3.2. Causes; 3.3. Risk Factors; 3.4. Symptoms; 3.5. Other Clinical Manifestation; 3.6. Prognosis Of Lupus Nephritis; 3.7. Clinical Presentation Of Lupus Nephritis; 3.8. Pathogenesis; 3.9. Classification; 3.9.1. Ln World Health Organization 1964 Classification; 3.9.2. Ln World Health Organization 1964 Classification; 3.9.3. World Health Organization (Who) Morphologic Classification Of Lupus Nephritis (Modified In 1982); 3.9.4. Ln World Health Organization 1964 Classification; 3.9.5. International Society Of Nephrology (Isn) And Renal Pathology Society (Rps) 2003 Classification For Ln; 3.9.6. Ln World Health Organization 1964 Classification; 3.10. Diagnosis
4. Epidemiology And Patient Population: 4.1. Key Findings
5. 7mm Total Prevalent Patient Population Of Ln
6. Country Wise-epidemiology Of Lupus Nephritis: 6.1. United States; 6.1.1. Assumptions And Rationale; 6.1.2. Total Prevalent Population Of Lupus Nephritis; 6.1.3. Total Diagnosed Population Of Lupus Nephritis; 6.1.4. Gender-specific Prevalent Population Of Lupus Nephritis; 6.1.5. Class- Specific Cases Of Lupus Nephritis; 6.1.6. Clinical Manifestations Of Lupus Nephritis; 6.2. Eu5 Countries; 6.2.1. Assumptions And Rationale; 6.3. Germany; 6.3.1. Total Prevalent Population Of Lupus Nephritis; 6.3.2. Total Diagnosed Population Of Lupus Nephritis; 6.3.3. Gender-specific Prevalent Population Of Lupus Nephritis; 6.3.4. Class- Specific Cases Of Lupus Nephritis; 6.3.5. Clinical Manifestations Of Lupus Nephritis; 6.4. France; 6.4.1. Total Prevalent Population Of Lupus Nephritis; 6.4.2. Total Diagnosed Population Of Lupus Nephritis; 6.4.3. Gender-specific Prevalent Population Of Lupus Nephritis; 6.4.4. Class- Specific Cases Of Lupus Nephritis; 6.4.5. Clinical Manifestations Of Lupus Nephritis; 6.5. Italy; 6.5.1. Total Prevalent Population Of Lupus Nephritis; 6.5.2. Total Diagnosed Population Of Lupus Nephritis; 6.5.3. Gender-specific Prevalent Population Of Lupus Nephritis; 6.5.4. Class- Specific Cases Of Lupus Nephritis; 6.5.5. Clinical Manifestations Of Lupus Nephritis; 6.6. United Kingdom; 6.6.1. Total Prevalent Population Of Lupus Nephritis; 6.6.2. Total Diagnosed Population Of Lupus Nephritis; 6.6.3. Gender-specific Prevalent Population Of Lupus Nephritis; 6.6.4. Class- Specific Cases Of Lupus Nephritis; 6.6.5. Clinical Manifestations Of Lupus Nephritis; 6.7. Spain; 6.7.1. Total Prevalent Population Of Lupus Nephrites; 6.7.2. Total Diagnosed Population Of Lupus Nephritis; 6.7.3. Gender-specific Prevalent Population Of Lupus Nephritis; 6.7.4. Class- Specific Cases Of Lupus Nephritis; 6.7.5. Clinical Manifestations Of Lupus Nephritis; 6.8. Japan; 6.8.1. Assumptions And Rationale; 6.8.2. Total Prevalent Population Of Lupus Nephrites; 6.8.3. Total Diagnosed Population Of Lupus Nephritis; 6.8.4. Gender-specific Prevalent Population Of Lupus Nephritis; 6.8.5. Class- Specific Cases Of Lupus Nephritis; 6.8.6. Clinical Manifestations Of Lupus Nephritis
7. Appendix: 7.1. Report Methodology
8. Delveinsight Capabilities
9. Disclaimer
10. About Delveinsight: Table 1: Total Prevalent Population Of Ln In The 7mm (2017-2028); Table 2: Total Prevalent Population Of Ln In The Us (2017-2028); Table 3: Diagnosed Cases Of Ln In The Us (2017-2028); Table 4: Gender Specific Prevalence Of Ln In The Us (2017-2028); Table 5: Class Specific Cases Of Ln In The Us (2017-2028); Table 6: Clinical Manifestations Of Ln In The Us (2017-2028); Table 7: Total Prevalent Population Of Ln In Germany (2017-2028); Table 8: Diagnosed Cases Of Ln In Germany (2017-2028); Table 9: Gender Specific Prevalence Of Ln In Germany (2017-2028); Table 10: Class Specific Cases Of Ln In Germany (2017-2028); Table 11: Clinical Manifestations Of Ln In Germany (2017-2028); Table 12: Total Prevalent Population Of Ln In France (2017-2028); Table 13: Diagnosed Cases Of Ln In France (2017-2028); Table 14: Gender Specific Prevalence Of Ln In France (2017-2028); Table 15: Class Specific Cases Of Ln In France (2017-2028); Table 16: Clinical Manifestations Of Ln In France (2017-2028); Table 17: Total Prevalent Population Of Ln In Italy (2017-2028); Table 18: Diagnosed Cases Of Ln In Italy (2017-2028); Table 19: Gender Specific Prevalence Of Ln In Italy (2017-2028); Table 20: Class Specific Cases Of Ln In Italy (2017-2028); Table 21: Clinical Manifestations Of Ln In Italy (2017-2028); Table 22: Total Prevalent Population Of Ln In The United Kingdom (2017-2028); Table 23: Diagnosed Cases Of Ln In The United Kingdom (2017-2028); Table 24: Gender Specific Prevalence Of Ln In The United Kingdom (2017-2028); Table 25: Class Specific Cases Of Ln In The United Kingdom (2017-2028); Table 26: Clinical Manifestations Of Ln In The United Kingdom (2017-2028); Table 27: Total Prevalent Population Of Ln In Spain (2017-2028); Table 28: Diagnosed Cases Of Ln In Spain (2017-2028); Table 29: Gender Specific Prevalence Of Ln In Spain (2017-2028); Table 30: Class Specific Cases Of Ln In Spain (2017-2028); Table 31: Clinical Manifestations Of Ln In Spain (2017-2028); Table 32: Total Prevalent Population Of Ln In Japan (2017-2028); Table 33: Diagnosed Cases Of Ln In Japan (2017-2028); Table 34: Gender Specific Prevalence Of Ln In Japan (2017-2028); Table 35: Class Specific Cases Of Ln In Japan (2017-2028); Table 36: Clinical Manifestations Of Ln In Japan (2017-2028); Table 1: Total Prevalent Population Of Ln In The 7mm (2017-2028); Table 2: Total Prevalent Population Of Ln In The Us (2017-2028); Table 3: Diagnosed Cases Of Ln In The Us (2017-2028); Table 4: Gender Specific Prevalence Of Ln In The Us (2017-2028); Table 5: Class Specific Cases Of Ln In The Us (2017-2028); Table 6: Clinical Manifestations Of Ln In The Us (2017-2028); Table 7: Total Prevalent Population Of Ln In Germany (2017-2028); Table 8: Diagnosed Cases Of Ln In Germany (2017-2028); Table 9: Gender Specific Prevalence Of Ln In Germany (2017-2028); Table 10: Class Specific Cases Of Ln In Germany (2017-2028); Table 11: Clinical Manifestations Of Ln In Germany (2017-2028); Table 12: Total Prevalent Population Of Ln In France (2017-2028); Table 13: Diagnosed Cases Of Ln In France (2017-2028); Table 14: Gender Specific Prevalence Of Ln In France (2017-2028); Table 15: Class Specific Cases Of Ln In France (2017-2028); Table 16: Clinical Manifestations Of Ln In France (2017-2028); Table 17: Total Prevalent Population Of Ln In Italy (2017-2028); Table 18: Diagnosed Cases Of Ln In Italy (2017-2028); Table 19: Gender Specific Prevalence Of Ln In Italy (2017-2028); Table 20: Class Specific Cases Of Ln In Italy (2017-2028); Table 21: Clinical Manifestations Of Ln In Italy (2017-2028); Table 22: Total Prevalent Population Of Ln In The United Kingdom (2017-2028); Table 23: Diagnosed Cases Of Ln In The United Kingdom (2017-2028); Table 24: Gender Specific Prevalence Of Ln In The United Kingdom (2017-2028); Table 25: Class Specific Cases Of Ln In The United Kingdom (2017-2028); Table 26: Clinical Manifestations Of Ln In The United Kingdom (2017-2028); Table 27: Total Prevalent Population Of Ln In Spain (2017-2028); Table 28: Diagnosed Cases Of Ln In Spain (2017-2028); Table 29: Gender Specific Prevalence Of Ln In Spain (2017-2028); Table 30: Class Specific Cases Of Ln In Spain (2017-2028); Table 31: Clinical Manifestations Of Ln In Spain (2017-2028); Table 32: Total Prevalent Population Of Ln In Japan (2017-2028); Table 33: Diagnosed Cases Of Ln In Japan (2017-2028); Table 34: Gender Specific Prevalence Of Ln In Japan (2017-2028); Table 35: Class Specific Cases Of Ln In Japan (2017-2028); Table 36: Clinical Manifestations Of Ln In Japan (2017-2028)Figure 1: Clinical Manifestations Of Sle And Lupus Nephritis; Figure 2: Risk Factors Of Lupus Nephritis; Figure 3: Symptoms Associated With Lupus Nephritis; Figure 4: Symptoms Associated With Lupus Nephritis; Figure 5: Lupus Nephritis Pathogenesis; Figure 6: Therapeutic Targets For Ln; Figure 7: Pathomechanisms Of Ln Outside The Kidney; Figure 8: Therapeutic Targets For Ln; Figure 9: Total Prevalent Patient Population Of Ln In The 7mm (2017-2028); Figure 10: Total Prevalent Population Of Ln In The Us (2017-2028); Figure 11: Diagnosed Cases Of Ln In The Us (2017-2028); Figure 12: Gender Specific Prevalence Of Ln In The Us (2017-2028); Figure 13: Class Specific Cases Of Ln In The Us (2017-2028); Figure 14: Clinical Manifestations Of Ln In The Us (2017-2028); Figure 15: Total Prevalent Population Of Ln In Germany (2017-2028); Figure 16: Diagnosed Cases Of Ln In Germany (2017-2028); Figure 17: Gender Specific Prevalence Of Ln In Germany (2017-2028); Figure 18: Class Specific Cases Of Ln In Germany (2017-2028); Figure 19: Clinical Manifestations Of Ln In Germany (2017-2028); Figure 20: Total Prevalent Population Of Ln In France (2017-2028); Figure 21: Diagnosed Cases Of Ln In France (2017-2028); Figure 22: Gender Specific Prevalence Of Ln In France (2017-2028); Figure 23: Class Specific Cases Of Ln In France (2017-2028); Figure 24: Clinical Manifestations Of Ln In France (2017-2028); Figure 25: Total Prevalent Population Of Ln In Italy (2017-2028); Figure 26: Diagnosed Cases Of Ln In Italy (2017-2028); Figure 27: Gender Specific Prevalence Of Ln In Italy (2017-2028); Figure 28: Class Specific Cases Of Ln In Italy (2017-2028); Figure 29: Clinical Manifestations Of Ln In Italy (2017-2028); Figure 30: Total Prevalent Population Of Ln In The United Kingdom (2017-2028); Figure 31: Diagnosed Cases Of Ln In The United Kingdom (2017-2028); Figure 32: Gender Specific Prevalence Of Ln In The United Kingdom (2017-2028); Figure 33: Class Specific Cases Of Ln In The United Kingdom (2017-2028); Figure 34: Clinical Manifestations Of Ln In The United Kingdom (2017-2028); Figure 35: Total Prevalent Population Of Ln In Spain (2017-2028); Figure 36: Diagnosed Cases Of Ln In Spain (2017-2028); Figure 37: Gender Specific Prevalence Of Ln In Spain (2017-2028); Figure 38: Class Specific Cases Of Ln In Spain (2017-2028); Figure 39: Clinical Manifestations Of Ln In Spain (2017-2028); Figure 40: Total Prevalent Population Of Ln In Japan (2017-2028); Figure 41: Diagnosed Cases Of Ln In Japan (2017-2028); Figure 42: Gender Specific Prevalence Of Ln In Japan (2017-2028); Figure 43: Class Specific Cases Of Ln In Japan (2017-2028); Figure 44: Clinical Manifestations Of Ln In Japan (2017-2028)